These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 24681744)

  • 1. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 3. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
    Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
    Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
    Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
    Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    Veskimäe K; Staff S; Tabaro F; Nykter M; Isola J; Mäenpää J
    Genes Chromosomes Cancer; 2015 May; 54(5):276-87. PubMed ID: 25706666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
    Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
    Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
    Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
    Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
    J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
    Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
    J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    Cheng A; Li L; Wu M; Lang J
    Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
    J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
    Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
    Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
    Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
    Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
    Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
    Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.